WWOX and succinic semialdehyde dehydrogenase deficiency: We were able to recommend targeted and personalized treatment for 11 patients; KCNT1-related epilepsy (No. 44) quinidine has been used as an off-label anticonvulsant (13, 14), molybdenum cofactor deficiency type A (No. 64) with cyclic pyranopterin monophosphate (cPMP) (15),Succinic semialdehyde dehydrogenase deficiency (No. 41) with vigabatrin (16), cerebral creatin deficiency (No. 39) with creatin monophosphate (17), WWOX gene mutation (N0.